nach oben

Erschienen in:

01.11.2011 | Original Article

Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer

verfasst von: William C. Zamboni, Austin J. Combest, Julie A. DeLoia, Robert P. Edwards, Arlene S. Bridges, Beth A. Zamboni, Christine M. Walko, Angela Y. C. Yu, Thomas C. Krivak, Joseph L. Kelley

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The objectives of this study were to determine whether the midazolam clearance predicted docetaxel pharmacokinetics, CA-125 change, and response and to assess the impact of cytochrome P450 (CYP) 3A5 and ATP-binding cassette, subfamily B, member 1 (ABCB1) genotypes on docetaxel pharmacokinetics and pharmacodynamics in ovarian or primary peritoneal cancer patients.

Methods

Thirty-four patients with advanced ovarian and primary peritoneal cancer were administered docetaxel at 75 mg/m² as a 1-h infusion in combination with carboplatin IV over 30 min at a target AUC of 5 mg/ml min. Cycles were repeated every 21 days for 6 cycles. Midazolam was administered at 2 mg as a 30-min IV infusion the day prior to cycle one of docetaxel administration. Pharmacokinetic studies of docetaxel and CYP3A5 and ABCB1 genotype studies were performed.

Results

There was an inverse relationship between midazolam clearance (CL) and CA-125 level after cycle 6 where a higher midazolam CL was associated with a CA-125 <10 U/ml (P = 0.007) and CA-125 <15 U/ml (P = 0.048). The CA-125 categories were associated with response achieved (complete response/partial response) (CR/PR), stable disease (SD), and progressive disease (PD) at the end of therapy (P = 0.0173). Docetaxel CL was not related to midazolam CL or genotype. Docetaxel exposure and genotypes were not related to toxicity or response (P > 0.05).

Conclusions

The midazolam CL predicted CA-125 levels and response that was independent of other factors including docetaxel pharmacokinetics. Future studies need to evaluate the mechanism for the relationship between midazolam CL and response in patients with ovarian cancer.

Gadducci A, Cosio S, Tana R et al (2009) Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol 69:12–27PubMedCrossRef

Ozols RF, Bundy BN, Fowler J et al (1999) Randomized phase III study of cisplatin (CIS) paclitaxel versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): a gynecologic oncology group trial (GOG 158). Proc Am Soc Clin Oncol 18:356a

Vorobiof DA, Rapoport BL, Chasen MR et al (2003) Phase II clinical trial of carboplatin and docetaxel in patients with metastatic ovarian cancer: active combination with low incidence of peripheral neuropathy. Int J Gynecol Cancer 13:287–291PubMedCrossRef

Vasey PA, Jayson GC, Gordon A et al (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96:1682–1691PubMedCrossRef

Lee JI, Chaves-Gnecco C, Amico JA et al (2002) Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther 72:718–727PubMedCrossRef

Goh BH, Lee SC, Wang LZ et al (2002) Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 20:3683–3690PubMedCrossRef

Lepper ER, Baker SD, Permenter M et al (2005) Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin Cancer Res 11:7398–7404PubMedCrossRef

Bosch TM, Huitema AD, Doodeman VD et al (2006) Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res 12:5786–5793PubMedCrossRef

Marsh S, Pau Jl, King CR, Gifford G, McLeod HL, Brown R (2007) Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish randomised trial in ovarian cancer. J Clin Oncol 25:4528–4535PubMedCrossRef

10.

Allen JD, Brinkhuis RF, van Deemter L et al (2000) Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res 60:5761–5766PubMed

11.

Van Zuylen L, Sparreboom A, Van der Gaast A et al (2002) Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. Eur J Cancer 38:1090–1099PubMedCrossRef

12.

Tran A, Jullien V, Alexandre J et al (2006) Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 79:570–580PubMedCrossRef

13.

Baker SD, Verweij J, Cusatis GA et al (2009) pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 85:155–163PubMedCrossRef

14.

Isla D, Sarries C, Rosell R et al (2004) Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15:1194–1203PubMedCrossRef

15.

Hou W, Watters JW, McLeod HL (2004) Simple and rapid docetaxel assay in plasma by protein precipitation and high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 804:263–267CrossRef

16.

Parise RA, Ramanathan RR, Zamboni WC, Egorin MJ (2003) Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma. J Chromatogr Anal Technol Biomed Life Sci 783:231–236CrossRef

17.

Kapron JT, Pace E, Van Pelt CK et al (2003) Quantitation of midazolam in human plasma by automated chip-based infusion nanoelectrospray tandem mass spectrometry. Rapid Commun Mass Spectrom 17:2019–2026PubMedCrossRef

18.

Marsh S, King CR, Garsa AA, McLeod HL (2005) Pyrosequencing of clinically relevant polymorphisms. Methods Mol Bio 311:91–114

19.

Therasse P, Arbuck SG, Eisenhauer EA (2000) New guidelines to evaluate the response to treatment in solid tumors. JNCI 92:205–216PubMedCrossRef

20.

Beatrice WT, Dnistrian A, Lloyd O (2002) Ovarian cancer antigen CA125 is encoded by the MUC16 Mucin gene. Int J Cancer 98:737–740CrossRef

21.

Epiney M, Bertossa C, Weil A, Campana A, Bischof P (2000) CA125 production by the peritoneum: in vitro and in vivo studies. Human Prod 15:1261–1265

22.

Crawford SM, Peace J (2005) Does the CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? Ann Oncol 16:47–50PubMedCrossRef

23.

Riedinger JM, Bonnetain F, Basuyau JP et al (2007) Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome. Ann Oncol 18:881–885PubMedCrossRef

24.

Teeling M, McGing P, Carney DN (1989) The prognostic value of post chemotherapy serum CA 125 in epithelial ovarian cancer. Ir J Med Sci 158:59–62PubMedCrossRef

Titel: Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer
verfasst von: William C. Zamboni
Austin J. Combest
Julie A. DeLoia
Robert P. Edwards
Arlene S. Bridges
Beth A. Zamboni
Christine M. Walko
Angela Y. C. Yu
Thomas C. Krivak
Joseph L. Kelley
Publikationsdatum: 01.11.2011
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 5/2011
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-011-1609-9

Springer Medizin

Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer